Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer.

Trends Mol Med

Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy; Gemelli Science and Technology Park (GSTeP) Organoids Research Core Facility, Fondazione Policlinico A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy. Electronic address:

Published: December 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by dismal prognosis. Late diagnosis, resistance to chemotherapy, and lack of efficacious targeted therapies render PDAC almost untreatable. Dysregulation of splicing, the process that excises the introns from nascent transcripts, is emerging as a hallmark of PDAC and a possible vulnerability of this devastating cancer. Splicing factors are deregulated in PDAC and contribute to all steps of tumorigenesis, from inflammation-related early events to metastasis and acquisition of chemoresistance. At the same time, splicing dysregulation offers a therapeutic opportunity to target cancer-specific vulnerabilities. We discuss mounting evidence that splicing plays a key role in PDAC and the opportunities that this essential process offers for developing new targeted therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2024.11.007DOI Listing

Publication Analysis

Top Keywords

splicing dysregulation
8
therapeutic opportunity
8
targeted therapies
8
splicing
5
pdac
5
dysregulation hallmark
4
hallmark therapeutic
4
opportunity pancreatic
4
pancreatic cancer
4
cancer pancreatic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!